Drug Profile
CD59 gene therapy
Alternative Names: Membrane attack complex inhibitor factor gene therapyLatest Information Update: 29 Jul 2021
Price :
$50
*
At a glance
- Originator Alexion Pharmaceuticals
- Class Gene therapies
- Mechanism of Action CD59 antigen agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Transplant rejection
Most Recent Events
- 21 Jul 2021 Alexion Pharmaceuticals has been acquired by AstraZeneca and changed its name to Alexion AstraZeneca Rare Disease
- 17 Mar 2003 Discontinued - Preclinical for Transplant rejection in USA (unspecified route)
- 30 Dec 2000 Discontinued - Preclinical for Transplant rejection in Australia (unspecified route)